Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) traded down 6.7% during mid-day trading on Tuesday ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have been assigned an average recommendation of “Buy” ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Shares of Soleno Therapeutics (NASDAQ:SLNO) fell by 6.7% after insider selling. Highlights:,Insider transactions have been ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target of ...

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...

Soleno Therapeutics, Inc.’s SLNO share price has surged by 35.80%, which has investors questioning if this is right time to ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...